Skip to main content
SpringerLink
Log in

Colony-Stimulating Factors

Present Status and Future Potential

  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) have been used successfully to enhance neutrophil recovery in patients with various malignancies undergoing standard or high dose chemotherapy, with or without autologous or allogeneic bone marrow transplantation support, and offer potential advantages in these settings in terms of reducing the total costs of healthcare and/or improving therapeutic outcomes. Clinical trials are now aimed at identifying which patients and which nonhaematological malignancies will respond best to colony-stimulating factor (CSF) support, and which of the 2 factors is the most appropriate in each setting. Two areas of considerable interest at present are the potential for chemotherapy dose optimisation and intensification with CSF therapy, and the use of CSFs to permit the harvest and reinfusion of peripheral blood progenitor cells as an alternative to autologous or allogeneic bone marrow transplantation. In the case of dose-intensified chemotherapy, costs of treatment increase but the gain may be an increase in survival rates or disease-free intervals.

The potential of G-CSF and GM-CSF therapy in other conditions, notably haematological malignancies such as myelodysplasia and myeloid leukaemias, and AIDS, means that these agents are likely to make a significant impact on the treatment of a wide range of debilitating conditions in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Goodnough LT, Anderson KC, Kurtz S, et al. Indications and guidelines for the use of hematopoietic growth factors. Transfusion 1993; 33: 944–59

    Article  PubMed  CAS  Google Scholar 

  2. Groopman JE, Molina J-M, Scadden DT. Haematopoietic growth factors. N Engl J Med 1989; 321: 1449–59

    Article  PubMed  CAS  Google Scholar 

  3. Schriber JR, Negrin RS. Use and toxicity of the colony-stimulating factors. Drug Safety 1993; 8: 457–68

    Article  PubMed  CAS  Google Scholar 

  4. Hollingshead LM, Goa KL. Recombinant granulocyte colonystimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions. Drugs 1991; 42: 300–30

    CAS  Google Scholar 

  5. Fossat C, Stoppa AM, Sainty D, et al. In vivo stimulation of neutrophil function by lenograstim (glycosylated rHuG-CSF) in oncohematologic patients: results of a phase I trial. Stem Cells 1994: 12: 322–8

    Article  PubMed  CAS  Google Scholar 

  6. Grant SM, Heel RC. Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF). A review of its pharmacological properties and prospective role in the management of myelosuppression. Drugs 1992; 43: 516–60

    CAS  Google Scholar 

  7. Gabrilove JL. Introduction and overview of hematopoietic growth factors. Semin Hematol 1989; 26 Suppl. 2: 1–4

    PubMed  CAS  Google Scholar 

  8. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (first of 2 parts). N Engl J Med 1992; 327: 28–35

    Article  PubMed  CAS  Google Scholar 

  9. Asano S. Human granulocyte colony-stimulating factor: its basic aspects and clinical applications. Am J Pediatr Hematol Oncol 1991; 13: 400–13

    Article  PubMed  CAS  Google Scholar 

  10. Steward WR Granulocyte and granulocyte-macrophage colony-stimulating factors. Lancet 1993; 342: 153–7

    Article  PubMed  CAS  Google Scholar 

  11. Nissen C, Dalle Carbonare V, Moser Y. In vitro comparison of the biological potency of glycosylated versus non-glycosylated rG-CSF. Drug Invest 1994; 7: 346–52

    Article  CAS  Google Scholar 

  12. Horgaard D, Mortensen BT, Schifter S, et al. Comparative pharmacokinetics of single-dose administration of mammalian and bacterially-derived recombinant human granulocytemacrophage colony-stimulating factor. Eur J Haematol 1993; 50: 32–6

    Article  Google Scholar 

  13. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (second of 2 parts). N Engl J Med 1992; 327: 99–106

    Article  PubMed  CAS  Google Scholar 

  14. Gisselbrecht C, Lepage E, Haioun C, et al. Lenograstim (glycosylated recombinant human G-CSF) supported chemotherapy optimisation in aggressive non Hodgkin’s lymphoma (NHL). Proc Am Soc Clin Oncol 1993; 12: 1226

    Google Scholar 

  15. Chevallier B, Chollet P, Merrouche Y, et al. Glycosylated rHuG-CSF (lenograstim) prevents morbidity from FEC-HD chemotherapy in inflammatory breast cancer (IBC). Proc Am Soc Clin Oncol 1993; 12: 84

    Google Scholar 

  16. Reyes F, Coiffier B, Lepage E, et al. Proceedings of the 5th International Conference on Malignant Lymphoma; 1993 Jun 9–12

  17. Miller LL. Current status of G-CSF in support of chemotherapy and radiotherapy. Oncology-Huntingt 1993; 7(10): 67–78, 81–83; discussion 83-84, 87-8

    PubMed  CAS  Google Scholar 

  18. Ariad S, Geffen D. Role of colony-stimulating factors during high dose chemotherapy. Clin Immunother 1994; 1: 449–59

    Article  Google Scholar 

  19. Gisselbrecht C, Prentice HG, Bacigalupo A, et al. Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation. Lancet 1994; 343: 696–700

    Article  PubMed  CAS  Google Scholar 

  20. Bronchud M. Can hematopoietic growth factors be used to improve the success of cytotoxic chemotherapy? Anticancer Drugs 1993; 4: 127–39

    Article  PubMed  CAS  Google Scholar 

  21. Ogawa M. The role of granulocyte colony-stimulating factor with dose-intensive therapy. Semin Oncol 1994; 21 Suppl. 1: 7–9

    PubMed  CAS  Google Scholar 

  22. Petros WP, Peters WP. Hematopoietic colony-stimulating factors and dose intensity. Semin Oncol 1993; 20: 94–9

    PubMed  CAS  Google Scholar 

  23. Woll PJ, Hodgetts J, Lomax L, et al. Use of rHuG-CSF (lenograstim) to dose intensify in small cell lung cancer (SCLC): A randomised study. Eur J Cancer 1993; 29A Suppl. 6: S154

    Article  Google Scholar 

  24. Bolwell BJ. The use of G-CSF and GM-CSF in bone marrow transplantation. Cleve Clin J Med 1993; 60: 291–302

    PubMed  CAS  Google Scholar 

  25. Bregni M, Siena S, Bonadonna G, et al. Clinical utilisation of human haematopoietic progenitors elicited in peripheral blood by recombinant human granulocyte colony-stimulating factor (rHuG-CSF). Eur J Cancer 1994; 30A: 235–8

    Article  PubMed  CAS  Google Scholar 

  26. Van Hoef MEHM, Baumann I, Lange C, et al. Dose-escalating induction chemotherapy supported by lenograstim preceding high-dose consolidation chemotherapy for advanced breast cancer. Ann Oncol 1994; 5: 217–24

    PubMed  Google Scholar 

  27. Sheridan WP, Begley CG, Juttner CA, et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640–44

    Article  PubMed  CAS  Google Scholar 

  28. Greenberg PL. Treatment of myelodysplastic syndromes with hemopoietic growth factors. Semin Oncol 1992; 19: 106–14

    PubMed  CAS  Google Scholar 

  29. Groopman JE, Feder D. Hematopoietic growth factors in AIDS. Semin Oncol 1992; 19: 408–14

    PubMed  CAS  Google Scholar 

  30. Faulds D, Lewis NJW, Milne RJ. Recombinant granulocyte colony-stimulating factor (rG-CSF). Pharmacoeconomic considerations in chemotherapy-induced neutropenia. PharmacoEconomics 1992; 1: 231–49

    CAS  Google Scholar 

  31. Glaspy JA, Bleecker G, Crawford J, et al. The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. Eur J Cancer 1993; 29A Suppl. 7: S23–30

    Article  PubMed  Google Scholar 

  32. Goa KL, Bryson HM. Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF). An appraisal of its pharmacoeconomic status in neutropenia associated with chemotherapy and autologous bone marrow transplant. PharmacoEconomics 1994; 5: 56–77

    CAS  Google Scholar 

  33. Brice P, Godin S, Libert O, et al. Effect of granulocyte colonystimulating factor (rHuG-CSF; lenograstim) on the cost of autologous bone marrow transplantation in the area of oncology and hematology. PharmacoEconomics. In press

  34. Petros WP, Peters WP. Cost implications of haematopoietic growth factors in the BMT setting. Bone Marrow Transplant 1993; 11 Suppl. 2: 36–8

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Haematology and Medical Oncology, Royal Melbourne Hospital, Melbourne, Victoria, 3050, Australia

    R. M. Fox

Authors
  1. R. M. Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fox, R.M. Colony-Stimulating Factors. Pharmacoeconomics 6 (Suppl 2), 1–8 (1994). https://doi.org/10.2165/00019053-199400062-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199400062-00003

Keywords

Search

Navigation